SPERO THERAPEUTICS INC (SPRO)

US84833T1034 - Common Stock

1.42  -0.02 (-1.05%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
18.26M
95.71%		53.51M
193.04%		103.781M
93.95%		49.198M
-52.59%
EBITDA
YoY % growth
-87.32M
-11.45%		-29.7M
65.99%		27.154M
191.43%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-87.97M
-11.20%		-30.57M
65.25%		26.787M
187.63%		-55.896M
-308.67%
Operating Margin
-481.76%-57.13%25.81%-113.61%
EPS
YoY % growth
-2.89
19.27%		-1.66
42.56%		0.52
131.33%		-0.96
-283.73%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.04
82.32%
Revenue
Q2Q % growth		21.964M
961.06%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-2.754M
80.65%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 0.96
74.55%		-0.101.061,041.18%
Q3 2023
Q2Q % growth		 0.04
112.12%		-0.030.07230.72%
Q2 2023
Q2Q % growth		 -0.23
73.56%		-0.350.1234.32%
Q1 2023
Q2Q % growth		 -0.25
75.25%		-0.340.0926.47%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 73.522M
54.98%		19.006M54.516M286.84%
Q3 2023
Q2Q % growth		 25.47M
1,167.16%		15.266M10.204M66.84%
Q2 2023
Q2Q % growth		 2.72M
36.68%		1.097M1.623M147.95%
Q1 2023
Q2Q % growth		 2.07M 1.02M1.05M102.94%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 79.03% -11.51% -56.98%
Revenue0% 187.11% -3.53% -26.92%